Expert consensus on the establishment and clinical application of patientderived endometrial cancer organoids

Abstract

Endometrial cancer (EC), the second most common gynaecologic malignancy, faces challenges in precision treatment due to limited predictive models for therapy selection. Patient-derived organoids, which recapitulate tumour heterogeneity and microenvironment, offer a transformative platform for drug sensitivity testing and personalised therapy. However, standardised protocols for establishing EC organoids, biobanking and clinical translation remain lacking consensus. This expert consensus proposes guidelines for EC organoid culture optimisation, characterisation and clinical validation. By harmonising technological advances with clinical needs, this consensus aims to accelerate the integration of organoid models into EC precision medicine, ultimately improving therapeutic outcomes.

Contributors All the authors participated in the conceptualisation and discussion. JW, XC and BZ performed the validation. YaC, YuC and CN wrote the manuscript.

Funding This research was supported by the Clinical Research Plan of SHDC (Grant No. SHDC2023CRT010), the national Key Technology R&D Program of China (Grant No. 2022YFC2704305) and Shanghai Municipal Health Commission Special Research Program on Emerging Interdisciplinary Fields (Grant No. 2022JC007)

Competing interests JW has served as the editorial-in-chief of GOCM. All other members of the expert group declare that there are no competing interests. JW has served as the editorial-in-chief of GOCM. XC has served as the editorial member of GOCM. All other members of the expert group declare that there are no competing interests.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See https://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Yali Cheng https://orcid.org/0000-0002-5117-0988

Jianliu Wang https://orcid.org/0000-0003-0338-0427

References

[1] Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl) 2022; 135:584-90.

[2] Ott PA, Bang Y-J, Berton-Rigaud D, et al. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. J Clin Oncol 2017; 35:2535-41.

[3] Hainsworth JD, Meric-Bernstam F, Swanton C, et al. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase Ila Multiple Basket Study. J Clin Oncol 2018; 36:536-42.

[4] Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 2020; 38:1-10.

[5] Oaknin A, Tinker AV, Gilbert L, et al. Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial. JAMA Oncol 2020; 6:1766-72.

[6] Gallos ID, Yap J, Rajkhowa M, et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2012; 207:266.

[7] Zeng M, Ruan Z, Tang J, et al. Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient mice. Cancer Cell Int 2023; 23:120.

[8] Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer 2018; 18:407-18.

[9] Yoshida GJ. Applications of patient-derived tumor xenograft models and tumor organoids. J Hematol Oncol 2020; 13:4.

[10] Clevers H. Modeling Development and Disease with Organoids. Cell 2016; 165:1586-97.

[11] Tuveson D, Clevers H. Cancer modeling meets human organoid technology. Science 2019; 364:952-5.

[12] Hu W, Lazar MA. Modelling metabolic diseases and drug response using stem cells and organoids. Nat Rev Endocrinol 2022; 18:744-59.

[13] Turco MY, Gardner L, Hughes J, et al. Long-term, hormoneresponsive organoid cultures of human endometrium in a chemically defined medium. Nat Cell Biol 2017; 19:568-77.

[14] Berg HF, Hjelmeland ME, Lien H, et al. Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis. Commun Med (Lond) 2021; 1:20.

[15] Katcher A, Yueh B, Ozler K, et al. Establishing patient-derived organoids from human endometrial cancer and normal endometrium. Front Endocrinol (Lausanne) 2023; 14:1059228.

[16] Barbi M, Gowthaman D, Katcher A, et al. Generation and Maintenance of Patient-Derived Endometrial Cancer Organoids. Bio Protoc 2024; 14:e5093.

[17] Maru Y, Tanaka N, Itami M, et al. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors. Gynecol Oncol 2019; 154:189-98.

[18] Boretto M, Maenhoudt N, Luo X, et al. Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening. Nat Cell Biol 2019; 21:1041-51.

[19] Bi J, Newtson AM, Zhang Y, et al. Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing. Cancers (Basel) 2021; 13:2901.

[20] Ren X, Liang J, Zhang Y, et al. Single-cell transcriptomic analysis highlights origin and pathological process of human endometrioid endometrial carcinoma. Nat Commun 2022; 13:6300.

[21] Gu Z-Y, Jia S-Z, Liu S, et al. Endometrial Organoids: A New Model for the Research of Endometrial-Related Diseases †. Biol Reprod 2020; 103:918-26.

[22] The Society of Cancer Multidisciplinary Diagnosis and Treatment, China Anti-Cancer Association, The Society of Cancer Endocrinology, China Anti-Cancer Association. Chinese experts consensus on quality control standards for tumor organoids diagnosis and treatment platform (2022 version). China Oncology 2022; 32:657-68.

[23] Driehuis E, Kretzschmar K, Clevers H. Establishment of patientderived cancer organoids for drug-screening applications. Nat Protoc 2020; 15:3380-409.

[24] Dekkers JF, van Vliet EJ, Sachs N, et al. Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids. Nat Protoc 2021; 16:1936-65.

[25] China SAo. GB/T 25915.1-2021 cleanrooms and associated controlled environments-part 1:classification of air cleanliness by particle concentration. Beijing China Standards Press; 2021.

[26] Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature New Biol 2009; 459:262-5.

[27] Cheng YL. Establishment of precision treatment for endometrial cancer with different molecular characteristics based on organoid high-throughput drug screening. Fudan University, 2025

[28] Buza N. Immunohistochemistry in gynecologic carcinomas: Practical update with diagnostic and clinical considerations based on the 2020 WHO classification of tumors. Semin Diagn Pathol 2022; 39:58-77.

[29] Zhao H, Lin N, Ho VWS, et al. Patient-Derived Bladder Cancer Organoids as a Valuable Tool for Understanding Tumor Biology and Developing Personalized Treatment. Adv Sci (Weinh) 2025;12.

[30] Kim S-Y, de Weert TAE, Vermeulen M, et al. Organoid drug profiling identifies methotrexate as a therapy for SCCOHT, a rare pediatric cancer. Sci Adv 2025;11.

[31] Zhou Z, Cong L, Cong X. Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank. Front Oncol 2021; 11:762184.

[32] Sachs N, de Ligt J, Kopper O, et al. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. Cell 2018; 172:373-86.

[33] Jacob F, Salinas RD, Zhang DY, et al. A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity. Cell 2020; 180:188-204.

[34] Beshiri ML, Tice CM, Tran C, et al. A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening. Clin Cancer Res 2018; 24:4332-45.

[35] Yan HHN, Siu HC, Law S, et al. A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening. Cell Stem Cell 2018; 23:882-97.

[36] Wensink GE, Elias SG, Mullenders J, et al. Patient-derived organoids as a predictive biomarker for treatment response in cancer patients. NPJ Precis Oncol 2021;5.

[37] Phan N, Hong JJ, Tofig B, et al. A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids. Commun Biol 2019;2.

[38] Group of expert consensus of clinical application about tumor precision therapy guided by organoid-based drug sensitivity testing (edition). Expert consensus of clinical application about tumor precision therapy guided by organoid-based drug sensitivity testing. Chin J Oncol Prev Treat 2022; 14:234-9.

[39] Vlachogiannis G, Hedayat S, Vatsiou A, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 2018; 359:920-6.

[40] Medical-Engineering Collaborative Group, Gastroenterology Branch of Chinese Medical Association. Chinese expert consensus on endoscopic biopsy and organoid culture techniques for gastrointestinal cancers (2024, Chengdu). Chinese Journal of Digestive Endoscopy 2024; 41:337-50.

[41] Boj SF, Hwang C-I, Baker LA, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 2015; 160:324-38.

[42] Sengal AT, Bonazzi V, Smith D, et al. Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition. NPJ Precis Oncol 2023;7.

[43] Kim M, Panagiotakopoulou M, Chen C, et al. Micro-engineering and nano-engineering approaches to investigate tumour ecosystems. Nat Rev Cancer 2023; 23:581-99.

[44] Liu H, Gan Z, Qin X, et al. Advances in Microfluidic Technologies in Organoid Research. Adv Healthcare Materials 2024;13.

[45] Yang X, Li K, Zhang X, et al. Nanofiber membrane supported lung-on-a-chip microdevice for anti-cancer drug testing. Lab Chip 2018; 18:486-95.

[46] Wang H, Ning X, Zhao F, et al. Human organoids-on-chips for biomedical research and applications. Theranostics 2024; 14:788-818.

[47] Yu T, Yang Q, Peng B, et al. Vascularized organoid-on-a-chip: design, imaging, and analysis. Angiogenesis 2024; 27:147-72.

[48] Nwokoye PN, Abilez OJ. Bioengineering methods for vascularizing organoids. Cell Rep Methods 2024;4.

[49] Mezghenna K, Leroy J, Azay-Milhau J, et al. Counteracting neuronal nitric oxide synthase proteasomal degradation improves glucose transport in insulin-resistant skeletal muscle from Zucker fa/fa rats. Diabetologia 2014; 57:177-86.

[50] Lim J, Ching H, Yoon J-K, et al. Microvascularized tumor organoids-on-chips: advancing preclinical drug screening with pathophysiological relevance. Nano Converg 2021;8.

[51] Jung DJ, Shin TH, Kim M, et al. A one-stop microfluidic-based lung cancer organoid culture platform for testing drug sensitivity. Lab Chip 2019; 19:2854-65.

[52] Pinho D, Santos D, Vila A, et al. Establishment of Colorectal Cancer Organoids in Microfluidic-Based System. Micromachines (Basel) 2021;12.

[53] Shirure VS, Bi Y, Curtis MB, et al. Tumor-on-a-chip platform to investigate progression and drug sensitivity in cell lines and patientderived organoids. Lab Chip 2018; 18:3687-702.

[54] Harter MF, Recaldin T, Gerard R, et al. Analysis of off-tumour toxicities of T-cell-engaging bispecific antibodies via donormatched intestinal organoids and tumouroids. Nat Biomed Eng 2024; 8:345-60.

[55] Ren T, Qui J, Chen F, et al. Targeting Glutamine Metabolism Transporter SLC25A 22 Enhances CD8+ T-Cell Function and Anti-PD-1 Therapy Efficacy in Cervical Squamous Cell Carcinoma: Integrated Metabolomics, Transcriptomics and T-Cell-Incorporated Tumor Organoid Studies. Adv Sci (Weinh) 2025; 12:e02225.

[56] Spiller ER, Ung N, Kim S, et al. Imaging-Based Machine Learning Analysis of Patient-Derived Tumor Organoid Drug Response. Front Oncol 2021;11.

[57] Okamoto T, Natsume Y, Doi M, et al. Integration of human inspection and artificial intelligence-based morphological typing of patientderived organoids reveals interpatient heterogeneity of colorectal cancer. Cancer Sci 2022; 113:2693-703.